Skip to content
DataLookout
Menu

NCT06612086

Dapagliflozin in Mangement of Pulmonary Hypertension Patients

StatusUnknown
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Not Yet Recruiting
  2. Notable Start date: Sep 21, 2024 to Oct 25, 2024v3 Show 5 more changesShow less
    • Primary endpoint revised
    • Study completion date: Oct 10, 2025 to Oct 10, 2026
    • Secondary endpoint revised
    • Publications: details revised at 5 of 7 entries
    • Study title shortened, about 1 word
  3. Minor Secondary endpoints: details revised at 1 of 1 entry
    • Study description revised
    v2
  4. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Effect of Dapagliflozin on Right ventricle systolic function in patient with pulmonary Hypertension by speckle tract Echocardiography(RV Strain )
Timeframe: 6 month

Secondary (1)

Effect of Dapagliflozin on Quality of life for patient with pulmonary hypertension by Kansas City Cardiomyopathy Questionnaire Score

Arms and interventions

we follow up patient who take Dapagliflozin in patient with pulmonary hypertensionExperimental

we follow up patient who take Dapagliflozin in patient with pulmonary hypertension

Drugs: Dapagliflozin (Forxiga)

Sites

1 site in 1 country

  • Assiut universityAsyut, Egypt